Skip to content

Micronutrient Supplementation Before and During 1st Pregnancy to Improve Birth Outcomes (JiVitA-5)

Micronutrient Supplementation Before and During 1st Pregnancy to Improve Birth Outcomes (JiVitA-5)

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03921177
Acronym
JiVitA-5
Enrollment
9859
Registered
2019-04-19
Start date
2019-01-17
Completion date
2021-05-29
Last updated
2021-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Birth Weight, Miscarriage, Preterm Birth, Small-for-gestational Age

Keywords

preconceptional multiple micronutrient supplementation, periconceptional multiple micronutrient supplementation, pregnancy outcomes, adolescent pregnancy, Bangladesh

Brief summary

The purpose of this cluster-randomized trial is to evaluate the efficacy of daily, multiple micronutrient (MM) supplement versus identical placebo use among nulligravid, recently married women, starting preconceptionally through the 1st trimester of pregnancy, in reducing low birth weight and other adverse pregnancy outcomes in rural Bangladesh.

Detailed description

Micronutrient deficiencies are common among women of reproductive age in rural South Asia, including Bangladesh. Antenatal multiple micronutrient (MM) supplementation, usually starting toward the end of the 1st trimester, has been shown to reduce low birth weight in many cultures. In northern Bangladesh, where the current study will be conducted, MM versus iron-folic acid supplementation has been shown to extend gestational age, thereby reducing risks of preterm birth 15% and low birth weight by 12%, and reduce risk of stillbirth by 11% (West KP et al. JAMA 2014), and to reduce risk of micronutrient deficiencies (Schulze KJ et al J Nutr 2019). Since it is plausible that women of reproductive age conceive in a state of lower micronutrient nutriture, it remains unknown the degree to which MM supplementation, starting preconceptionally through the 1st trimester (covering the periconceptional and embryonic period) can benefit pregnancy outcome. Further, there is concern that newlywed, nulligravid women in rural South Asia are at high risk, and may be at particular health and pregnancy risks due to micronutrient deficiencies resulting from dietary inadequacy. The investigators propose to conduct a double-masked, cluster-randomized, placebo-controlled trial among recently married women in 18 rural unions of Gaibandha District, Bangladesh, that will provide a daily tablet containing either (a) a MM formulation containing a US Institute of Medicine (IOM) Recommended Dietary Allowance (RDA) for pregnancy for 15 essential vitamins and minerals (and closely approximates the UNIMAP formula), or (b) a placebo tablet of identical appearance containing no micronutrients, during a period extending from at least one-month prior to last menstrual period through the 1st trimester of pregnancy (\ 12 weeks' gestation). The study area will comprise 566 rural clusters (sectors) each with 250-400 households, serving as units of randomization. Consenting, recently married women will be detected through routine community surveillance and start to receive coded, double-masked supplements, resupplied during monthly home visits. Participating women will receive coded supplements for daily consumption until the end of the trial or until determined to be pregnant. On detection of pregnancy by a history of amenorrhea confirmed by urine test, irrespective of randomized allocation, all women will be switched to receive an open-labeled MM supplement, expected to occur toward the end of the 1st trimester, which will continue through 3 months post-partum. This switch is in response to previous positive effects shown on pregnancy outcomes with a MM supplement starting at the end of the 1st trimester. Participating married women will be periodically interviewed for socioeconomic, morbidity, dietary and lifestyle risk factors and assessed by anthropometry. Pregnancies will be followed for miscarriage, abortion, live birth and still birth outcomes. Newborn anthropometry will be assessed to determine birth weight and size. Infants and mothers will be eligible for additional breast feeding, dietary, morbidity and growth assessments at 8 days, and 1, 3 and 6 months after delivery. Participating women resident in a predefined subset of the study area (n\ 68 sectors) will receive enhanced assessments, including blood draw in the end of the 1st trimester for subsequent laboratory assessment of micronutrient status, and body composition, among other measures.

Interventions

Preconception to 12-weeks gestation: daily (coded) multiple micronutrient supplement containing 15-nutrients (vitamins and minerals) providing an approximate recommended dietary allowance for pregnant women, approximating the UNICEF UNIMAP formulation (UN micronutrient preparation).

DRUGPlacebo Oral Tablet

Preconception to 12-weeks gestation: identical tablet

Sponsors

JiVitA Project, Gaibandha, Bangladesh
CollaboratorUNKNOWN
Johns Hopkins Bloomberg School of Public Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

Multiple micronutrient and placebo tablets are identical in size, shape, and appearance; coding of supplements carried out independent of investigators and research team.

Intervention model description

Cluster-randomized, placebo-controlled concurrent intervention trial

Eligibility

Sex/Gender
FEMALE
Age
No minimum to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Resident of 566 rural sectors (clusters) in Gaibandha district * Recently-married woman * Nulligravid

Exclusion criteria

* Women with a history of previous pregnancy * Women who refuse consent for participation

Design outcomes

Primary

MeasureTime frameDescription
Preterm Birth - number of live-births occurring earlier than 37 weeks gestation among all live-births (with known gestational age)up to 38 weeks of gestationPregnancies ending in a live birth less than 37 weeks' gestation
Miscarriage - number of spontaneous abortions occurring earlier than 24 weeks gestation among all pregnancies (with known gestational age)up to 24 weeks gestationPregnancies ending as a spontaneous abortion less than 24 weeks' gestation
Small for Gestational Age - number of live-born neonates weighing less than the 10th centile of birth weight for gestational age and sex among all live-births (with known gestational age and birth weight)up to 72 hours after live birthInfants weighing less than the 10th centile of birth weight for gestational age and sex
Low Birth Weight - number of live-born neonates weighing less than 2500 g at birth among all live-births (with known birth weight)Measured from time of live birth through 72 hours after birthInfants weighing less than 2500 g at birth

Secondary

MeasureTime frameDescription
Folate StatusMeasured at 12 weeks gestationDistribution of total plasma folate, nmol/L
Anemia in Pregnant WomenMeasured at 12 weeks gestationHemoglobin in whole blood, less than a cutoff of 110 g/L
Selenium StatusMeasured at 12 weeks gestationDistribution of total plasma selenium, ng/mL
Vitamin B12 StatusMeasured at 12 weeks gestationDistribution of total plasma cobalamin, pmol/L
Iron StatusMeasured at 12 weeks gestationDistribution of plasma ferritin, ng/mL
Vitamin A StatusMeasured at 12 weeks gestationDistribution of plasma retinol, micromoles/L
Vitamin E StatusMeasured at 12 weeks gestationDistribution of plasma alpha-tocopherol, micromoles/L

Countries

Bangladesh

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026